{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T23:40:47Z","timestamp":1794440447517,"version":"4.9.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2013,3,20]],"date-time":"2013-03-20T00:00:00Z","timestamp":1363737600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1245\/s10434-013-2942-5","type":"journal-article","created":{"date-parts":[[2013,3,19]],"date-time":"2013-03-19T06:18:28Z","timestamp":1363673908000},"page":"1444-1450","source":"Crossref","is-referenced-by-count":209,"title":["Inherited Mutations in Pheochromocytoma and Paraganglioma: Why All Patients Should Be Offered Genetic Testing"],"prefix":"10.1245","volume":"20","author":[{"given":"Lauren","family":"Fishbein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shana","family":"Merrill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas L.","family":"Fraker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie L.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine L.","family":"Nathanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,3,20]]},"reference":[{"key":"2942_CR1","volume-title":"World Health Organization classification of tumours. Pathology and genetics of tumours of endocrine organs","year":"2004","unstructured":"DeLellis RA, Lloyd RV, Heitz PU, Eng C, editors. World Health Organization classification of tumours. Pathology and genetics of tumours of endocrine organs. Lyon, France: IARC Press; 2004."},{"key":"2942_CR2","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1055\/s-0032-1306275","volume":"44","author":"M Mannelli","year":"2012","unstructured":"Mannelli M, Dralle H, Lenders JW. Perioperative management of pheochromocytoma\/paraganglioma: is there a state of the art? Horm Metab Res. 2012;44:373\u20138.","journal-title":"Horm Metab Res."},{"key":"2942_CR3","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1097\/HJH.0b013e32834a4ce9","volume":"29","author":"A Prejbisz","year":"2011","unstructured":"Prejbisz A, Lenders JW, Eisenhofer G, Januszewicz A. Cardiovascular manifestations of pheochromocytoma. J Hypertens. 2011;29:2049\u201360.","journal-title":"J Hypertens."},{"key":"2942_CR4","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/MPA.0b013e3181ebb4f0","volume":"39","author":"H Chen","year":"2010","unstructured":"Chen H, Sippel RS, O\u2019Dorisio MS, Vinik AI, Lloyd RV, Pacak K. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas. 2010;39:775\u201383.","journal-title":"Pancreas."},{"key":"2942_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cancergen.2012.01.009","volume":"205","author":"L Fishbein","year":"2012","unstructured":"Fishbein L, Nathanson KL. Pheochromocytoma and paraganglioma: understanding the complexities of the genetic background. Cancer Genet. 2012;205:1\u201311.","journal-title":"Cancer Genet."},{"key":"2942_CR6","doi-asserted-by":"crossref","first-page":"R253","DOI":"10.1530\/ERC-11-0170","volume":"18","author":"J Welander","year":"2011","unstructured":"Welander J, Soderkvist P, Gimm O. Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. Endocr Relat Cancer. 2011;18:R253\u201376.","journal-title":"Endocr Relat Cancer."},{"key":"2942_CR7","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1210\/jc.2010-1946","volume":"96","author":"M Ayala-Ramirez","year":"2011","unstructured":"Ayala-Ramirez M, Feng L, Johnson MM, et al. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab. 2011;96:717\u201325.","journal-title":"J Clin Endocrinol Metab."},{"key":"2942_CR8","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1210\/jc.2008-2419","volume":"94","author":"M Mannelli","year":"2009","unstructured":"Mannelli M, Castellano M, Schiavi F, et al. Clinically guided genetic screening in a large cohort of Italian patients with pheochromocytomas and\/or functional or nonfunctional paragangliomas. J Clin Endocrinol Metab. 2009;94:1541\u20137.","journal-title":"J Clin Endocrinol Metab."},{"key":"2942_CR9","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1056\/NEJMoa020152","volume":"346","author":"HP Neumann","year":"2002","unstructured":"Neumann HP, Bausch B, McWhinney SR, et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med. 2002;346:1459\u201366.","journal-title":"N Engl J Med."},{"key":"2942_CR10","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1158\/0008-5472.CAN-08-4057","volume":"69","author":"HP Neumann","year":"2009","unstructured":"Neumann HP, Erlic Z, Boedeker CC, et al. Clinical predictors for germline mutations in head and neck paraganglioma patients: cost reduction strategy in genetic diagnostic process as fall-out. Cancer Res. 2009;69:3650\u20136.","journal-title":"Cancer Res."},{"key":"2942_CR11","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/gcc.20268","volume":"45","author":"M Aarts","year":"2006","unstructured":"Aarts M, Dannenberg H, deLeeuw RJ, et al. Microarray-based CGH of sporadic and syndrome-related pheochromocytomas using a 0.1\u20130.2\u00a0Mb bacterial artificial chromosome array spanning chromosome arm 1p. Genes Chromosomes Cancer. 2006;45:83\u201393.","journal-title":"Genes Chromosomes Cancer"},{"key":"2942_CR12","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1126\/science.287.5454.848","volume":"287","author":"BE Baysal","year":"2000","unstructured":"Baysal BE, Ferrell RE, Willett-Brozick JE, et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science. 2000;287:848\u201351.","journal-title":"Science."},{"key":"2942_CR13","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1093\/hmg\/ddq206","volume":"19","author":"N Burnichon","year":"2010","unstructured":"Burnichon N, Briere JJ, Libe R, et al. SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet. 2010;19:3011\u201320.","journal-title":"Hum Mol Genet."},{"key":"2942_CR14","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1126\/science.1175689","volume":"325","author":"HX Hao","year":"2009","unstructured":"Hao HX, Khalimonchuk O, Schraders M, et al. SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science. 2009;325:1139\u201342.","journal-title":"Science."},{"key":"2942_CR15","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/81551","volume":"26","author":"S Niemann","year":"2000","unstructured":"Niemann S, Muller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet. 2000;26:268\u201370.","journal-title":"Nat Genet."},{"key":"2942_CR16","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S1470-2045(10)70007-3","volume":"11","author":"JP Bayley","year":"2010","unstructured":"Bayley JP, Kunst HP, Cascon A, et al. SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma. Lancet Oncol. 2010;11:366\u201372.","journal-title":"Lancet Oncol."},{"key":"2942_CR17","doi-asserted-by":"crossref","first-page":"E1472","DOI":"10.1210\/jc.2011-1043","volume":"96","author":"E Korpershoek","year":"2011","unstructured":"Korpershoek E, Favier J, Gaal J, et al. SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas. J Clin Endocrinol Metab. 2011;96:E1472\u20136.","journal-title":"J Clin Endocrinol Metab."},{"key":"2942_CR18","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1158\/1078-0432.CCR-10-0420","volume":"17","author":"HP Kunst","year":"2011","unstructured":"Kunst HP, Rutten MH, de Monnink JP, et al. SDHAF2 (PGL2-SDH5) and hereditary head and neck paraganglioma. Clin Cancer Res. 2011;17:247\u201354.","journal-title":"Clin Cancer Res."},{"key":"2942_CR19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10689-004-0621-1","volume":"4","author":"U Muller","year":"2005","unstructured":"Muller U, Troidl C, Niemann S. SDHC mutations in hereditary paraganglioma\/pheochromocytoma. Fam Cancer. 2005;4:9\u201312.","journal-title":"Fam Cancer."},{"key":"2942_CR20","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jama.292.8.943","volume":"292","author":"HP Neumann","year":"2004","unstructured":"Neumann HP, Pawlu C, Peczkowska M, et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA. 2004;292:943\u201351.","journal-title":"JAMA."},{"key":"2942_CR21","doi-asserted-by":"crossref","first-page":"8812","DOI":"10.1200\/JCO.2005.03.1484","volume":"23","author":"L Amar","year":"2005","unstructured":"Amar L, Bertherat J, Baudin E, et al. Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol. 2005;23:8812\u20138.","journal-title":"J Clin Oncol."},{"key":"2942_CR22","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.otohns.2007.01.015","volume":"137","author":"CC Boedeker","year":"2007","unstructured":"Boedeker CC, Neumann HP, Maier W, Bausch B, Schipper J, Ridder GJ. Malignant head and neck paragangliomas in SDHB mutation carriers. Otolaryngol Head Neck Surg. 2007;137:126\u20139.","journal-title":"Otolaryngol Head Neck Surg."},{"key":"2942_CR23","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1210\/jc.2006-0423","volume":"91","author":"FM Brouwers","year":"2006","unstructured":"Brouwers FM, Eisenhofer G, Tao JJ, et al. High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. J Clin Endocrinol Metab. 2006;91:4505\u20139.","journal-title":"J Clin Endocrinol Metab."},{"key":"2942_CR24","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/humu.21136","volume":"31","author":"CJ Ricketts","year":"2010","unstructured":"Ricketts CJ, Forman JR, Rattenberry E, et al. Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD. Hum Mutat. 2010;31:41\u201351.","journal-title":"Hum Mutat."},{"key":"2942_CR25","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1365-2265.2008.03274.x","volume":"69","author":"U Srirangalingam","year":"2008","unstructured":"Srirangalingam U, Walker L, Khoo B, et al. Clinical manifestations of familial paraganglioma and phaeochromocytomas in succinate dehydrogenase B (SDH-B) gene mutation carriers. Clin Endocrinol (Oxf). 2008;69:587\u201396.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2942_CR26","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1210\/jc.2006-2315","volume":"92","author":"HJ Timmers","year":"2007","unstructured":"Timmers HJ, Kozupa A, Eisenhofer G, et al. Clinical presentations, biochemical phenotypes, and genotype\u2013phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas. J Clin Endocrinol Metab. 2007;92:779\u201386.","journal-title":"J Clin Endocrinol Metab."},{"key":"2942_CR27","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1136\/jmg.39.3.178","volume":"39","author":"BE Baysal","year":"2002","unstructured":"Baysal BE, Willett-Brozick JE, Lawrence EC, et al. Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas. J Med Genet. 2002;39:178\u201383.","journal-title":"J Med Genet."},{"key":"2942_CR28","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1677\/ERC-08-0284","volume":"16","author":"HJ Timmers","year":"2009","unstructured":"Timmers HJ, Gimenez-Roqueplo AP, Mannelli M, Pacak K. Clinical aspects of SDHx-related pheochromocytoma and paraganglioma. Endocr Relat Cancer. 2009;16:391\u2013400.","journal-title":"Endocr Relat Cancer."},{"key":"2942_CR29","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/ng.861","volume":"43","author":"I Comino-Mendez","year":"2011","unstructured":"Comino-Mendez I, Gracia-Aznarez FJ, Schiavi F, et al. Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet. 2011;43:663\u20137.","journal-title":"Nat Genet."},{"key":"2942_CR30","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/ng.533","volume":"42","author":"Y Qin","year":"2010","unstructured":"Qin Y, Yao L, King EE, et al. Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nat Genet. 2010;42:229\u201333.","journal-title":"Nat Genet."},{"key":"2942_CR31","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1158\/1078-0432.CCR-12-0160","volume":"18","author":"N Burnichon","year":"2012","unstructured":"Burnichon N, Cascon A, Schiavi F, et al. MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clin Cancer Res. 2012;18:2828\u201337.","journal-title":"Clin Cancer Res."},{"key":"2942_CR32","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1001\/jama.2010.1830","volume":"304","author":"L Yao","year":"2010","unstructured":"Yao L, Schiavi F, Cascon A, et al. Spectrum and prevalence of FP\/TMEM127 gene mutations in pheochromocytomas and paragangliomas. JAMA. 2010;304:2611\u20139.","journal-title":"JAMA."},{"key":"2942_CR33","doi-asserted-by":"crossref","first-page":"E1279","DOI":"10.1210\/jc.2011-0114","volume":"96","author":"HP Neumann","year":"2011","unstructured":"Neumann HP, Sullivan M, Winter A, et al. Germline mutations of the TMEM127 gene in patients with paraganglioma of head and neck and extraadrenal abdominal sites. J Clin Endocrinol Metab. 2011;96:E1279\u201382.","journal-title":"J Clin Endocrinol Metab."},{"key":"2942_CR34","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/jmg.2006.045906","volume":"44","author":"RE Ferner","year":"2007","unstructured":"Ferner RE, Huson SM, Thomas N, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet. 2007;44:81\u20138.","journal-title":"J Med Genet."},{"key":"2942_CR35","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1373\/clinchem.2010.153320","volume":"57","author":"G Eisenhofer","year":"2011","unstructured":"Eisenhofer G, Lenders JW, Timmers H, et al. Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. Clin Chem. 2011;57:411\u201320.","journal-title":"Clin Chem."},{"key":"2942_CR36","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1055\/s-2008-1073156","volume":"40","author":"G Eisenhofer","year":"2008","unstructured":"Eisenhofer G, Siegert G, Kotzerke J, Bornstein SR, Pacak K. Current progress and future challenges in the biochemical diagnosis and treatment of pheochromocytomas and paragangliomas. Horm Metab Res. 2008;40:329\u201337.","journal-title":"Horm Metab Res."},{"key":"2942_CR37","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/S1470-2045(09)70164-0","volume":"10","author":"FH Nederveen van","year":"2009","unstructured":"van Nederveen FH, Gaal J, Favier J, et al. An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol. 2009;10:764\u201371.","journal-title":"Lancet Oncol."},{"key":"2942_CR38","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/PAS.0b013e3181d6150d","volume":"34","author":"AJ Gill","year":"2010","unstructured":"Gill AJ, Chou A, Vilain R, et al. Immunohistochemistry for SDHB divides gastrointestinal stromal tumors (GISTs) into 2 distinct types. Am J Surg Pathol. 2010;34:636\u201344.","journal-title":"Am J Surg Pathol."},{"key":"2942_CR39","doi-asserted-by":"crossref","unstructured":"American Society of Clinical Oncology. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol. 2003;21:2397\u2013406.","DOI":"10.1200\/JCO.2003.03.189"},{"key":"2942_CR40","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1210\/jc.2008-2504","volume":"94","author":"N Burnichon","year":"2009","unstructured":"Burnichon N, Rohmer V, Amar L, et al. The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas. J Clin Endocrinol Metab. 2009;94:2817\u201327.","journal-title":"J Clin Endocrinol Metab."},{"key":"2942_CR41","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1210\/jc.2008-2756","volume":"94","author":"A Cascon","year":"2009","unstructured":"Cascon A, Pita G, Burnichon N, et al. Genetics of pheochromocytoma and paraganglioma in Spanish patients. J Clin Endocrinol Metab. 2009;94:1701\u20135.","journal-title":"J Clin Endocrinol Metab."},{"key":"2942_CR42","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1210\/jc.2005-1862","volume":"91","author":"DE Benn","year":"2006","unstructured":"Benn DE, Gimenez-Roqueplo AP, Reilly JR, et al. Clinical presentation and penetrance of pheochromocytoma\/paraganglioma syndromes. J Clin Endocrinol Metab. 2006;91:827\u201336.","journal-title":"J Clin Endocrinol Metab."},{"key":"2942_CR43","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s10689-010-9402-1","volume":"10","author":"EF Hensen","year":"2011","unstructured":"Hensen EF, Bayley JP. Recent advances in the genetics of SDH-related paraganglioma and pheochromocytoma. Fam Cancer. 2011;10:355\u201363.","journal-title":"Fam Cancer."},{"key":"2942_CR44","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2009.27.0660","volume":"28","author":"ME Robson","year":"2010","unstructured":"Robson ME, Storm CD, Weitzel J, Wollins DS, Offit K. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol. 2010;28:893\u2013901.","journal-title":"J Clin Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-013-2942-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-013-2942-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-013-2942-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T22:10:02Z","timestamp":1595542202000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-013-2942-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,20]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["2942"],"URL":"https:\/\/doi.org\/10.1245\/s10434-013-2942-5","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,20]]}}}